4/A: Artivion SVP, Clinical & MD Affairs, Marshall S. Stanton, Reports Changes in Beneficial Ownership
SEC Form 4/A (Amendment to Statement of Changes in Beneficial Ownership)
Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc., filed an amendment to his Form 4, reporting the acquisition and disposition of common stock on March 1, 2024, due to the vesting of performance stock units and a correction of a previous reporting error.
Summary
- On March 1, 2024, Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc., acquired 5,724 shares of common stock at $0 related to LTIP performance stock units.
- On the same day, Stanton disposed of 1,506 shares at $18.7221 to cover tax withholding obligations upon the vesting of performance stock units.
- Following these transactions, Stanton beneficially owns 85,479 shares of Artivion, Inc.
- This filing is an amendment to a previous Form 4 filed on March 7, 2024, correcting an administrative error in reporting the number of shares sold on February 26, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The correction of an error is slightly positive as it shows attention to detail.
Positives
- The acquisition of shares through LTIP performance stock units indicates a potential alignment of Stanton's interests with the company's performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, which is common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Comparison to Industry Standards
- Executive compensation practices, including the use of LTIPs and performance stock units, are common across the medical device industry.
- Companies like Medtronic, Boston Scientific, and Abbott also utilize similar equity-based compensation plans to incentivize and retain key personnel.
- Form 4 filings are a standard requirement for insiders of publicly traded companies in the United States, ensuring transparency and preventing insider trading.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of the sell to cover transactions with an administrative error in reporting the number of shares sold. |
| 03/01/2024 | Date of the reported transactions: acquisition of 5,724 shares and disposition of 1,506 shares. |
| 03/07/2024 | Date of the original Form 4 filing that this document amends. |
| 03/14/2024 | Date of this amended filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.